InVivo Therapeutics at Meeting on the Mesa

InVivo Therapeutics Video Presentation at Alliance for Regenerative Medicine 6th Annual Partnering Forum
Tom Ulich, M.D., Chief Scientific Officer, Cambridge, MA (NASDAQ: NVIV)

Posted in Biomaterials, Chronic Spinal Cord Injury Research, Regenerative Medicine, Spinal Research | Tagged , , | Leave a comment

Oligodendrocyte Progenitor Cells and Scar Ablation for Chronic SCI – Dr. Ann Parr

Dr. Ann Parr

Dr. Ann Parr

In this Working 2 Walk 2016 presentation, Dr. Parr details the work in her lab on two projects: Development of autologous OPC’s, and use of rose bengal for removing the glial scar.

Ann M. Parr, MD, PhD, is a Board Certified Neurosurgeon who is interested in finding new therapies for spinal cord injury. She is also a faculty member in the Graduate Program in Neuroscience and the Stem Cell Institute at the University of Minnesota. Dr. Parr’s research currently centers around transplanting neural stem cells grown from a patient’s own skin into the injured spinal cord. She has an active translational research laboratory at the University of Minnesota Stem Cell Institute. She is interested in examining mechanisms of functional recovery using techniques such as histology, immunohistochemistry, cell tracking through magnetic resonance imaging and animal modeling.

Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, Spinal Research, Stem Cell Research, Unite 2 Fight Paralysis, Working 2 Walk Science & Advocacy Symposium | Tagged | Leave a comment

Spinal Cord Injury and Neural Stem Cells by Mark H. Tuszynski

Presentation Video: Spinal Cord Injury and Neural Stem Cells by Mark H. Tuszynski, MD, PhD at the 5th Annual Symposium on Regenerative Rehabilitation

Dr. Mark Tuszynski

Dr. Mark Tuszynski


UC San Diego School of Medicine Link:

Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, Spinal Research, Stem Cell Research | Tagged | Leave a comment

Chondroitinase Clinical Trial for Dogs Submits Data to Journal

Iowa State University  college of Vet Medicine Chondroitinase Dog Trial

Iowa State University college of Vet Medicine Chondroitinase Dog Trial

From the Iowa State University of Vet Medicine
Hello Clinical Trial Friends and Families!
We have now officially completed the clinical trial and the key points are: (1) chondroitinase ABC has no detectable side effects in our 60 patients, meaning that it is a relatively safe drug based on our observations; (2) while a group effect is not detectable, there is evidence suggestive of some potential treatment effect in a subset of patients (e.g. 10% of the Treatment group patients regained ambulation after one month and the bladder test result also improved in Treatment group after one month); (3) future research should probably focus on adjusting the drug dosage, means of delivery and patient selection (e.g. choosing patients that are more likely to benefit from the treatment, such as those that already have some function in their back legs).

The study will be written up and submitted to a medical/scientific journal by early next year. The reviewing process may take a while but we will keep you posted!

Thank you so much for your participation and support!
Clinical Trial Team

STUDY ABSTRACT:
Traumatic spinal cord injury is a devastating neurologic condition in both veterinary and human medicine and despite research yielding numerous potential interventions with remarkable efficacy demonstrated in rodent models, none has advanced to successful clinical translation. Pet dogs’ predilection for sustaining spinal cord injury, typically due to intervertebral disc herniation or vertebral column fracture, makes them a suitable clinical model in which putative interventions for spinal cord injury can be tested. In recent years, there has been a growing body of experimental evidence that attests to the efficacy of chondroitinase ABC in promoting axonal regeneration and functional recovery after spinal cord injury by reactivating neuroplasticity. Chondroitinase ABC is a commercialized bacterial enzyme that selectively deglycosylates chondroitin sulfate proteoglycans and thereby disrupts the perineuronal nets that limits axonal regeneration. In this 60-dog clinical trial, we examined the therapeutic effect of chondroitinase ABC on the primary outcome measure, pelvic-thoracic limb gait coordination, and several secondary parameters, including motor- and sensory-evoked potentials and urinary bladder compliance. While our study failed to detect a therapeutic effect in chronic, severe thoracolumbar spinal-injured dogs, it has established drug safety in a clinical large animal model. Thus, this study has provided a platform for future investigations in which the dose, route and timing of chondroitinase ABC administration, as well as patient selection, can be adjusted to maximize its potential therapeutic effect and benefit spinal-injured human and veterinary patients, especially if a more treatment-responsive subgroup could be identified.

Posted in Chronic Spinal Cord Injury Research, Neuroscience Abstracts, Rehabilitation | Tagged , , | Leave a comment

Translation of Biomaterial Based Therapies for Spinal Cord Injury – Dr. Alex Aimetti

Dr. Alex Aimetti - InVivo

Dr. Alex Aimetti – InVivo

Dr. Aimetti talks about the clinical and pre-clinical advancements made by InVivo Therapeutics to develop treatments for acute and chronic spinal cord injury.

Alex Aimetti, PhD, is Senior Director, Medical Education and Scientific Support at InVivo Therapeutics. InVivo is a research and clinical-stage biomaterials and biotechnology company with a focus on innovative treatment approaches for spinal cord injury (SCI). Alex joined InVivo in 2012 and currently serves as the lead for all professional medical education programs that aim to build company, technology, and product awareness. Alex’s scientific research has resulted in over 40 top-tiered scientific publications, conference presentations, and patent applications within the biomaterials and regenerative medicine fields. Prior to joining InVivo, Alex completed his post-doctoral fellowship in the lab of Robert Langer at the Massachusetts Institute of Technology (MIT). Alex has a PhD in Chemical Engineering and a BS in Biomedical Engineering.

See other presentations by Dr. Alex Aimetti HERE.

Posted in Biomaterials, Chronic Spinal Cord Injury Research, Regenerative Medicine, Spinal Research, Unite 2 Fight Paralysis, Working 2 Walk Science & Advocacy Symposium | Tagged | Leave a comment

Neurokinex chosen as first international NeuroRecovery Community Fitness and Wellness Affiliate

Neurokinex chosen as the first international NeuroRecovery Community Fitness and Wellness Affiliate of the Christopher & Dana Reeve Foundation

Neurokinex

Neurokinex

This brings breakthrough neurological rehabilitation treatments to the UK and Europe.

Neurokinex – the UK’s leading provider of neurological activity-based rehabilitation – has been chosen as the first international Community Fitness and Wellness Affiliate of the Reeve Foundation’s NeuroRecovery Network (NRN). This affiliation means that Neurokinex can deliver the unique NRN protocols and bring its ground-breaking work within reach of people in the UK and Europe.

The Reeve Foundation NRN is a cooperative network of cutting-edge rehabilitation sites designed to develop and deliver therapies that promote functional recovery to improve the health and quality of life for people living with paralysis. With the addition of Neurokinex, the NRN has expanded to include 12 sites.

READ THE FULL STORY AT THIS LINK

Posted in Chronic Spinal Cord Injury Research, Rehabilitation, Spinal Research | Tagged , | 2 Comments

Spinal Cord Injury Consumer Engagement in Research – Dr. Kim Anderson-Erisman

Dr. Kim Anderson-Erisman PhD

Dr. Kim Anderson-Erisman PhD

Dr. Anderson-Erisman details the many opportunities in the following video presentation that are and will become available for persons with SCI to influence both the amount and focus of research funding.

Kim Anderson-Erisman, PhD, is a Research Associate Professor and the Director of Education for The Miami Project to Cure Paralysis at the University of Miami Miller School of Medicine. Her research has focused on translational investigations and bridging the gap between basic science, clinical science, and the public community living with spinal cord injury (SCI). Her training spans the spectrum of SCI research, from cellular and molecular studies, to whole animal and behavioral studies, to human clinical research. She has conducted a multi-center clinical study evaluating the reliability and validity of the Spinal Cord Independence Measure in the US healthcare setting. Several of her studies have focused on obtaining the perspective of people living with SCI on various aspects of research, including functional priorities, acceptable benefits and risks, preferences for neuroprosthetics, and exercise participation. Her current projects focus on 1) aging related changes in bladder health after SCI, 2) determining the minimum amount of exercise and locomotor training required for clinical trials targeting chronic SCI, and 3) identifying the facilitators and barriers to clinical trial participation from the SCI consumer perspective. In addition to pursuing her own research regarding chronic injury, she is part of the leadership team running the Schwann cell transplantation clinical trials at the University of Miami.

Posted in Chronic Spinal Cord Injury Research, Rehabilitation, Spinal Research, Unite 2 Fight Paralysis, Working 2 Walk Science & Advocacy Symposium | Tagged | Leave a comment

Restoring Function With Neurotechnology – Megan Moynahan

Megan Moynahan

Megan Moynahan

Over the last several decades, neurotechnologies have successfully demonstrated the ability to restore hand function, trunk stability, respiration, bladder, bowel function, standing and stepping for people with spinal cord injury. However, few have made it to commercial reality. This presentation explores the pathway to commercialization and what we might expect to see in coming years.

Megan Moynahan, MS, is the Executive Director of the Institute for Functional Restoration (IFR), a non-profit organization based at Case Western Reserve University that has the mission to restore function to people with spinal cord injury by building a sustainable commercial enterprise for neuromodulation systems. The IFR’s unique commercialization approach assures the steady translation of proven technologies out of research and into stable commercial availability. The IFR is currently shepherding a multi-function neuromodulation system through the regulatory and commercialization stages, with the support from both philanthropy and traditional grants. She holds a BS in Biomedical Engineering from Johns Hopkins University and a MS in Biomedical Engineering from Case Western Reserve University.

Posted in Chronic Spinal Cord Injury Research, Rehabilitation, Spinal Research, Unite 2 Fight Paralysis, Working 2 Walk Science & Advocacy Symposium | Tagged | Leave a comment

Combined chronic theta burst stimulation of motor cortex and trans-spinal direct current stimulation in rats promote coticospinal tract outgrowth caudal to a cervical spinal contusion and motor recovery

Authors:
M. SHINOZAKI1, *N. ZAREEN2, D. RYAN2, H. ALEXANDER2, S. NAEEM3, J. H. MARTIN4;
1Keio Univ. Sch. of Med., Tokyo, Japan; 2Physiology, Pharmacol. and Neurosci., 3Sophie Davis/CUNY Sch. of Med., 4The Grad. Center, CUNY, NY, The City Col. of the City Univ. of NY, New York, NY

An important strategy for promoting motor function after SCI is to augment sprouting of the spared axons of motor pathways. We showed in a rat pyramidal tract lesion model that motor cortex (M1) electrical stimulation augments sprouting of spared corticospinal tract (CST) axons and promotes motor recovery (Carmel et al, 2010). In the present study, we translated M1 stimulation to a moderate cervical contusion injury. We modified our published M1 stimulation protocol and used an intermittent theta burst electrical stimulation (iTBS) pattern. We combined iTBS with spinal cord cathodal DC stimulation to co-activate spinal circuits during M1 stimulation, based on our recent pyramidal tract lesion study (Song et al 2016). We examined CST axonal labeling caudal to the injury and several behavioral outcomes in 2 animal groups: injury only (n=14); injury + combined iTBS and cervical spinal DC stimulation (n=13). Bilateral contusions (Infinite Horizons; 200kdyn) were made at the C4 level. Stimulation began 7 days after injury and continued for 10 days for 30 minutes daily. iTBS was delivered through epidural electrodes bilaterally over forelimb M1 and cervical cathodal DC stimulation, through cutaneous electrodes. Analyses were done blind. There were no differences in lesion volume between the two groups. Nor were there differences in the number of spared CST axons in the white matter for the two groups. We measured total CST axon length and axon varicosity number within the C6 gray matter. As expected, for both groups gray matter axon length increased as the number of spared CST axons in the white matter increased. However, this relationship was greater for the stimulated group, where there was approximately a 2-fold increase in axon length per spared white matter CST axon. A similar increase in CST axon varicosities (ie., presynaptic sites) was observed for the stimulated compared with non-stimulated group. Von Frey hair testing revealed no change in either group, relative to uninjured controls. For the IBB test, there was no difference in initial post-injury scores for the two groups and only the stimulated group showed a significant improvement compared with the non-stimulated group (non-stimulated: 7.4%; paired t-test; p=0.31; stimulated: 17.7%; p=0.009). Analyses are in progress to determine treatment effect on locomotion (horizontal ladder walking and treadmill). Our findings show that combined M1 and spinal cord cathodal DC stimulation promoted spared CST axonal outgrowth and significantly improved forepaw manipulation skills after a moderate cervical contusion injury.

Disclosures
M. Shinozaki: None. N. Zareen: None. D. Ryan: None. H. Alexander: None. S. Naeem: None. J.H. Martin: None.

Link Session 059 – Training, Rehabilitation, and Repair: Spinal Cord Injury Recovery

Posted in Chronic Spinal Cord Injury Research, Neuroscience Abstracts, Rehabilitation, Spinal Research | Tagged , | Leave a comment

U2FP Advocates Fire Up SCI Research Funding at W2W

Building on the successful model developed in Minnesota, U2FP Advocacy Director Matthew Rodreick is working with local advocates in additional states to pursue research funding at the state level. In Pennsylvania, the local group has already had a bill introduced into the legislature and Washington is soon to follow. Georgia and Wisconsin are the new targets and preliminary conversations have begun with community members there. We invite and welcome additional advocates to help champion the cause. Contact matthewrodreick@u2fp.org for more information on how you can become part of the Cure Advocacy Network.

The follow up presentation to NASCAR and The Conestoga Wagon Train was a primer for how the MN legislators saw our SCI community’s advocacy effort. They told the story from their perspective providing valuable insights into what makes sense to a legislators priorities.

Posted in Advocacy, Chronic Spinal Cord Injury Research, Spinal Research, Unite 2 Fight Paralysis, Working 2 Walk Science & Advocacy Symposium | Leave a comment